Vericel price to free cash flow VCEL

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: 35.3×
6-year median: 92.8×
Against its 6-year history: 3rd; percentile: 0 is its lowest day, 100 its highest
6-year range: 31.8× to 313×
Peer median: 28.2×

Vericel's price to free cash flow is 35.3× as of Oct 23, 2026.

That is below its 6-year median of 92.8×, lower than on 97% of days in the last 6 years.

Over that time it ranged from 31.8× in Sep 2026 to 313× in Feb 2021.

The median for 8 biotech stocks of a similar size is 28.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	35.3×	31.8×	95.7×
2025	93.5×	89.5×	99.9×
2024	151×	82.1×	164×
2023	89.9×	71.6×	155×
2022	90.1×	63.4×	118×
2021	84.3×	76.5×	313×
2020	188×	68.6×	188×

Against its peers

Companies in Biotechnology nearest Vericel's size, closest first, today.

Company	Price to free cash flow
VCELVericel	35.3×
ADMAAdma Biologics	20.5×
MGTXMeiraGTx	84.5×
KRYSKrystal Biotech	35.8×
RGENRepligen	89.2×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
Peer median	28.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Vericel

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.